Market Update – November 01, 2019

We have been making the case that the U.S. economy is doing just fine and the equity market is not overvalued by conventional metrics. This week it was announced that the U.S. economy grew at an annualized pace of 1.9%, above what most economist thought. On the market side, the S&P 500 is trading at 16.7x next year’s earnings; the 25-year average is 16.22x[i]. We have positive growth in the economy and the markets are healthy, therefore we don’t think a recession is likely in the near term.

Market Update – October 25, 2019

In last week’s Market Update, we discussed the importance of this earnings season. For most of the year, there have been two school of thoughts; either things are not going well in the economy and a recession is near or the growth in the U.S. economy is not great, but it is still moving forward and a recession is not imminent.

Market Update – September 27, 2019

In last week’s Market Update, we discussed the Fed cut and low yields. We wrote about the low and flat bond yield curve and low yields on the S&P 500, which have driven investors to stocks that have paid an attractive, reliable and increasing dividend. We also introduced the alternatives asset class; another area that we think will benefit from the current yield environment. The three main asset classes are: stocks, bonds and cash; alternative assets are everything else, such as private equity, private credit and private real estate.

Driven To Cure

It is with a heavy heart that we announce of the passing of Surevest client, Andrew Lee. He passed away Easter Sunday April 21st 2019 at age 23. Four years earlier he was diagnosed with a rare kidney cancer, hereditary leiomyomatosis and renal cell cancer (HLRCC), which currently has no known cure. Doctors told Andrew he may only have a year to live. With this news, Andrew and his family immediately looked for any new clinical trial which might help him. Andrew was referred to The National Institute of Health where research through clinical trials is having some success for HLRCC. 
Andrew volunteered for 7 different experimental trials, sometimes being the first one to receive the new treatment. Andrew approached each clinical trial with a positive attitude. More incredible is what Andrew created during his short time; Driven To Cure.

Market Update – August 23, 2019

The second quarter earnings results are wrapping up and the numbers are better than expected. At the end of the second quarter, the consensus believed earnings would decline in the S&P 500 by -2.7% (Year-over-Year)[i]. As of market close on Thursday, 96% of companies had reported their numbers and it appears the final number will not be as bad as analyst thought.